Blog

Cytori shares slammed as safety concerns halt stem cell trials – FierceBiotech

Cytori shares slammed as safety concerns halt stem cell trials
FierceBiotech
Cytori Therapeutics ($CYTX) hit the brakes on a pair of clinical trials to find out why three patients in the study suffered from "cerebrovascular" events after they were treated with the biotech's experimental stem cell treatment. The San Diego-based
Cytori halts stem cell study due to adverse eventsBusinessweek



all 27 news articles »

2014-08-06 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.